25 XP   0   0   10

Hanall Biopharma
Buy, Hold or Sell?

Let's analyse Hanall together

PenkeI guess you are interested in Hanall Biopharma. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Hanall Biopharma. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Hanall Biopharma

I send you an email if I find something interesting about Hanall Biopharma.

Quick analysis of Hanall (30 sec.)










What can you expect buying and holding a share of Hanall? (30 sec.)

How much money do you get?

How much money do you get?
₩0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
₩3,673.23
Expected worth in 1 year
₩4,027.53
How sure are you?
65.0%

+ What do you gain per year?

Total Gains per Share
₩354.31
Return On Investment
1.0%

For what price can you sell your share?

Current Price per Share
₩35,300.00
Expected price per share
₩28,550 - ₩46,750
How sure are you?
50%

1. Valuation of Hanall (5 min.)




Live pricePrice per Share (EOD)

₩35,300.00

Intrinsic Value Per Share

₩292.04 - ₩265.44

Total Value Per Share

₩3,965.27 - ₩3,938.67

2. Growth of Hanall (5 min.)




Is Hanall growing?

Current yearPrevious yearGrowGrow %
How rich?$130.3m$109.9m$17.3m13.6%

How much money is Hanall making?

Current yearPrevious yearGrowGrow %
Making money$614k$44k$569.9k92.8%
Net Profit Margin1.3%0.2%--

How much money comes from the company's main activities?

3. Financial Health of Hanall (5 min.)




What can you expect buying and holding a share of Hanall? (5 min.)

Welcome investor! Hanall's management wants to use your money to grow the business. In return you get a share of Hanall.

What can you expect buying and holding a share of Hanall?

First you should know what it really means to hold a share of Hanall. And how you can make/lose money.

Speculation

The Price per Share of Hanall is ₩35,300. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Hanall.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Hanall, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ₩3,673.23. Based on the TTM, the Book Value Change Per Share is ₩88.58 per quarter. Based on the YOY, the Book Value Change Per Share is ₩31.53 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ₩0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Hanall.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps-0.040.0%0.010.0%0.000.0%0.040.0%0.020.0%
Usd Book Value Change Per Share-0.160.0%0.060.0%0.020.0%0.050.0%0.040.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.160.0%0.060.0%0.020.0%0.050.0%0.040.0%
Usd Price Per Share31.01-20.31-11.81-18.03-14.63-
Price to Earnings Ratio-196.10-238.08--1,563.51--231.35--77.50-
Price-to-Total Gains Ratio-195.88--100.82--35.63--95.07--155.98-
Price to Book Ratio12.06-7.99-5.47-8.38-8.42-
Price-to-Total Gains Ratio-195.88--100.82--35.63--95.07--155.98-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share24.71
Number of shares40
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.060.05
Usd Total Gains Per Share0.060.05
Gains per Quarter (40 shares)2.481.94
Gains per Year (40 shares)9.927.78
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1010008-2
2020100166
30302002314
40403003122
50504003930
60605004738
70696005446
80797006254
90898007062
100999007870

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share2.02.00.050.0%6.06.00.050.0%14.06.00.070.0%26.09.05.065.0%26.09.09.059.1%
Book Value Change Per Share2.02.00.050.0%5.07.00.041.7%13.07.00.065.0%26.014.00.065.0%27.017.00.061.4%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.044.00.0%
Total Gains per Share2.02.00.050.0%5.07.00.041.7%13.07.00.065.0%26.014.00.065.0%27.017.00.061.4%

Fundamentals of Hanall

About Hanall Biopharma

Hanall Biopharma Co., Ltd., a pharmaceutical company, manufactures and sells pharmaceutical products in South Korea and internationally. The company offers prescription drugs and over-the-counter products for the treatment of diarrhea, prostatic hyperplasia, androgenetic alopecia, chronic renal failure, hypoparathyroidism, vitamin D-resistant rickets, osteomalacia, osteoporosis, prostate cancer, toxic liver disease, chronic hepatitis, liver cirrhosis, male pattern baldness, functional dyspepsia, diabetes, bacterial infections, peripheral vascular disorders, hypertension, chronic heart failure, skin diseases, hypoproteinemia, diabetic polyneuritis, ulcers, high blood pressure, arthritis, endocrine disorders, spasms, insomnia, muscle pain, hypoproteinemia, gastroesophageal reflux disease, allergic rhinitis, conjunctivitis, dermatitis, chronic urticaria, cholesterol cholelithiasis, gastritis, neurological diseases, erectile dysfunction, hyperphosphatemia, urinary tract infection, spastic paralysis, fungal infections, dysmenorrhea, hypercholesterolemia, constipation, abdominal distension, abdominal fermentation in the intestines, neuralgia, capillary weakness, post-phlebitis syndrome, irritable bowel syndrome, spastic colon, and hemorrhoids, as well as vitamin D, vitamin B1, vitamin B12, and calcium deficiency. It develops products in the fields of ophthalmology, immunology, oncology, and neurology, such as HL192 for Parkinson's disease; HL036 for dry eye disease; HL161 for myasthenia gravis, thyroid eye disease, warm autoimmune hemolytic anemia, neuromyelitis optica, immune thrombocytopenia, chronic inflammatory demyelinating polyneuropathy, and graves' disease; and HL187 and HL186 for immuno-oncology. The company was founded in 1973 and is headquartered in Daejeon, South Korea.

Fundamental data was last updated by Penke on 2024-04-14 23:14:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is inefficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Hanall Biopharma.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Hanall earns for each ₩1 of revenue.

  • Above 10% is considered healthy but always compare Hanall to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of -9.0% means that ₩-0.09 for each ₩1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Hanall Biopharma:

  • The MRQ is -9.0%. The company is making a loss. -1
  • The TTM is 1.3%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ-9.0%TTM1.3%-10.3%
TTM1.3%YOY0.2%+1.1%
TTM1.3%5Y10.0%-8.7%
5Y10.0%10Y6.5%+3.5%
1.1.2. Return on Assets

Shows how efficient Hanall is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Hanall to the Drug Manufacturers - Specialty & Generic industry mean.
  • -1.2% Return on Assets means that Hanall generated ₩-0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Hanall Biopharma:

  • The MRQ is -1.2%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is 0.4%. Using its assets, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ-1.2%TTM0.4%-1.6%
TTM0.4%YOY0.0%+0.3%
TTM0.4%5Y1.3%-0.9%
5Y1.3%10Y0.9%+0.4%
1.1.3. Return on Equity

Shows how efficient Hanall is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Hanall to the Drug Manufacturers - Specialty & Generic industry mean.
  • -1.5% Return on Equity means Hanall generated ₩-0.02 for each ₩1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Hanall Biopharma:

  • The MRQ is -1.5%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is 0.5%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ-1.5%TTM0.5%-2.0%
TTM0.5%YOY0.0%+0.5%
TTM0.5%5Y1.7%-1.2%
5Y1.7%10Y1.2%+0.5%

1.2. Operating Efficiency of Hanall Biopharma.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Hanall is operating .

  • Measures how much profit Hanall makes for each ₩1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Hanall to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0% means the company generated ₩0.00  for each ₩1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Hanall Biopharma:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY1.2%-1.2%
TTM-5Y7.4%-7.4%
5Y7.4%10Y4.6%+2.9%
1.2.2. Operating Ratio

Measures how efficient Hanall is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 1.67 means that the operating costs are ₩1.67 for each ₩1 in net sales.

Let's take a look of the Operating Ratio trends of Hanall Biopharma:

  • The MRQ is 1.671. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.449. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.671TTM1.449+0.222
TTM1.449YOY1.152+0.297
TTM1.4495Y1.258+0.191
5Y1.25810Y1.093+0.166

1.3. Liquidity of Hanall Biopharma.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Hanall is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 3.02 means the company has ₩3.02 in assets for each ₩1 in short-term debts.

Let's take a look of the Current Ratio trends of Hanall Biopharma:

  • The MRQ is 3.017. The company is very able to pay all its short-term debts. +2
  • The TTM is 3.544. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.017TTM3.544-0.528
TTM3.544YOY4.360-0.816
TTM3.5445Y4.869-1.325
5Y4.86910Y3.584+1.285
1.3.2. Quick Ratio

Measures if Hanall is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Hanall to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 1.02 means the company can pay off ₩1.02 for each ₩1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Hanall Biopharma:

  • The MRQ is 1.020. The company is just able to pay all its short-term debts with the most liquid assets.
  • The TTM is 1.582. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ1.020TTM1.582-0.562
TTM1.582YOY2.669-1.087
TTM1.5825Y3.309-1.727
5Y3.30910Y2.723+0.586

1.4. Solvency of Hanall Biopharma.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Hanall assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Hanall to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.22 means that Hanall assets are financed with 22.3% credit (debt) and the remaining percentage (100% - 22.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Hanall Biopharma:

  • The MRQ is 0.223. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.208. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.223TTM0.208+0.016
TTM0.208YOY0.187+0.020
TTM0.2085Y0.215-0.007
5Y0.21510Y0.246-0.031
1.4.2. Debt to Equity Ratio

Measures if Hanall is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Hanall to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 28.7% means that company has ₩0.29 debt for each ₩1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Hanall Biopharma:

  • The MRQ is 0.287. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.263. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.287TTM0.263+0.025
TTM0.263YOY0.231+0.032
TTM0.2635Y0.277-0.014
5Y0.27710Y0.348-0.071

2. Market Valuation of Hanall Biopharma

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₩1 in earnings Hanall generates.

  • Above 15 is considered overpriced but always compare Hanall to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of -196.10 means the investor is paying ₩-196.10 for every ₩1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Hanall Biopharma:

  • The EOD is -156.261. Based on the earnings, the company is expensive. -2
  • The MRQ is -196.101. Based on the earnings, the company is expensive. -2
  • The TTM is 238.083. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-156.261MRQ-196.101+39.840
MRQ-196.101TTM238.083-434.184
TTM238.083YOY-1,563.514+1,801.598
TTM238.0835Y-231.349+469.432
5Y-231.34910Y-77.503-153.846
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Hanall Biopharma:

  • The EOD is 446.799. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is 560.714. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is 143.147. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD446.799MRQ560.714-113.915
MRQ560.714TTM143.147+417.567
TTM143.147YOY-906.379+1,049.526
TTM143.1475Y-109.042+252.189
5Y-109.04210Y-31.681-77.361
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Hanall is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of 12.06 means the investor is paying ₩12.06 for each ₩1 in book value.

Let's take a look of the Price to Book Ratio trends of Hanall Biopharma:

  • The EOD is 9.610. Based on the equity, the company is overpriced. -1
  • The MRQ is 12.060. Based on the equity, the company is expensive. -2
  • The TTM is 7.994. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD9.610MRQ12.060-2.450
MRQ12.060TTM7.994+4.066
TTM7.994YOY5.465+2.529
TTM7.9945Y8.384-0.390
5Y8.38410Y8.425-0.041
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Hanall Biopharma compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---226.16388.576-355%31.527-817%69.432-426%62.427-462%
Book Value Per Share--3673.2293585.130+2%3089.587+19%3113.629+18%2450.109+50%
Current Ratio--3.0173.544-15%4.360-31%4.869-38%3.584-16%
Debt To Asset Ratio--0.2230.208+7%0.187+19%0.215+4%0.246-9%
Debt To Equity Ratio--0.2870.263+9%0.231+24%0.277+4%0.348-17%
Dividend Per Share----0%-0%-0%-0%
Eps---56.47617.302-426%1.244-4639%50.439-212%31.593-279%
Free Cash Flow Per Share--19.752100.823-80%86.437-77%35.104-44%58.412-66%
Free Cash Flow To Equity Per Share--19.752100.823-80%34.205-42%23.221-15%87.600-77%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%0.875+14%
Intrinsic Value_10Y_max--265.438--------
Intrinsic Value_10Y_min--292.042--------
Intrinsic Value_1Y_max--172.185--------
Intrinsic Value_1Y_min--169.213--------
Intrinsic Value_3Y_max--406.392--------
Intrinsic Value_3Y_min--390.215--------
Intrinsic Value_5Y_max--506.836--------
Intrinsic Value_5Y_min--479.982--------
Market Cap1789572330000.000-25%2245837230000.0001470820601250.000+53%858034768325.000+162%1314157377622.500+71%1065711012861.250+111%
Net Profit Margin---0.0900.013-790%0.002-4814%0.100-190%0.065-239%
Operating Margin----0%0.012-100%0.074-100%0.046-100%
Operating Ratio--1.6711.449+15%1.152+45%1.258+33%1.093+53%
Pb Ratio9.610-25%12.0607.994+51%5.465+121%8.384+44%8.425+43%
Pe Ratio-156.261+20%-196.101238.083-182%-1563.514+697%-231.349+18%-77.503-60%
Price Per Share35300.000-25%44300.00029012.500+53%16875.000+163%25752.500+72%20894.250+112%
Price To Free Cash Flow Ratio446.799-25%560.714143.147+292%-906.379+262%-109.042+119%-31.681+106%
Price To Total Gains Ratio-156.082+20%-195.877-100.818-49%-35.631-82%-95.074-51%-155.979-20%
Quick Ratio--1.0201.582-36%2.669-62%3.309-69%2.723-63%
Return On Assets---0.0120.004-407%0.000-3138%0.013-191%0.009-234%
Return On Equity---0.0150.005-409%0.000-3512%0.017-189%0.012-229%
Total Gains Per Share---226.16388.576-355%31.527-817%69.432-426%62.427-462%
Usd Book Value--130352858.881127226469.122+2%109911509.680+19%111159956.588+17%87423218.056+49%
Usd Book Value Change Per Share---0.1580.062-355%0.022-817%0.049-426%0.044-462%
Usd Book Value Per Share--2.5712.510+2%2.163+19%2.180+18%1.715+50%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.0400.012-426%0.001-4639%0.035-212%0.022-279%
Usd Free Cash Flow--700930.5313577919.310-80%3067293.868-77%1244780.389-44%1821195.805-62%
Usd Free Cash Flow Per Share--0.0140.071-80%0.061-77%0.025-44%0.041-66%
Usd Free Cash Flow To Equity Per Share--0.0140.071-80%0.024-42%0.016-15%0.061-77%
Usd Market Cap1252700631.000-25%1572086061.0001029574420.875+53%600624337.828+162%919910164.336+71%745997709.003+111%
Usd Price Per Share24.710-25%31.01020.309+53%11.813+163%18.027+72%14.626+112%
Usd Profit---2004180.913614006.323-426%44007.868-4654%1805827.367-211%1130357.608-277%
Usd Revenue--22202706.97423609221.584-6%19249198.357+15%19024390.452+17%16859637.740+32%
Usd Total Gains Per Share---0.1580.062-355%0.022-817%0.049-426%0.044-462%
 EOD+4 -4MRQTTM+7 -25YOY+7 -265Y+7 -2610Y+11 -23

3.2. Fundamental Score

Let's check the fundamental score of Hanall Biopharma based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-156.261
Price to Book Ratio (EOD)Between0-19.610
Net Profit Margin (MRQ)Greater than0-0.090
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than11.020
Current Ratio (MRQ)Greater than13.017
Debt to Asset Ratio (MRQ)Less than10.223
Debt to Equity Ratio (MRQ)Less than10.287
Return on Equity (MRQ)Greater than0.15-0.015
Return on Assets (MRQ)Greater than0.05-0.012
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of Hanall Biopharma based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5052.127
Ma 20Greater thanMa 5034,392.500
Ma 50Greater thanMa 10035,830.000
Ma 100Greater thanMa 20035,759.500
OpenGreater thanClose35,350.000
Total4/5 (80.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Tax Provision  953,713-688,944264,769742,3891,007,158-815,190191,968-1,961,939-1,769,971



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in KRW. All numbers in thousands.

Summary
Total Assets239,746,993
Total Liabilities53,528,623
Total Stockholder Equity186,218,370
 As reported
Total Liabilities 53,528,623
Total Stockholder Equity+ 186,218,370
Total Assets = 239,746,993

Assets

Total Assets239,746,993
Total Current Assets113,577,189
Long-term Assets126,169,803
Total Current Assets
Cash And Cash Equivalents 33,722,514
Short-term Investments 22,774,597
Net Receivables 15,630,329
Inventory 32,384,161
Other Current Assets 179,635
Total Current Assets  (as reported)113,577,189
Total Current Assets  (calculated)104,691,236
+/- 8,885,954
Long-term Assets
Property Plant Equipment 19,433,937
Intangible Assets 32,609,078
Long-term Assets  (as reported)126,169,803
Long-term Assets  (calculated)52,043,015
+/- 74,126,788

Liabilities & Shareholders' Equity

Total Current Liabilities37,651,870
Long-term Liabilities15,876,753
Total Stockholder Equity186,218,370
Total Current Liabilities
Accounts payable 11,272,575
Other Current Liabilities 2,097,298
Total Current Liabilities  (as reported)37,651,870
Total Current Liabilities  (calculated)13,369,873
+/- 24,281,997
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt1,290,530
Long-term Liabilities  (as reported)15,876,753
Long-term Liabilities  (calculated)1,290,530
+/- 14,586,223
Total Stockholder Equity
Retained Earnings 31,364,999
Total Stockholder Equity (as reported)186,218,370
Total Stockholder Equity (calculated)31,364,999
+/- 154,853,371
Other
Capital Stock26,120,319
Common Stock Shares Outstanding 50,693
Net Invested Capital 186,218,370
Net Working Capital 75,925,319
Property Plant and Equipment Gross 50,830,110



Balance Sheet

Currency in KRW. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-31
> Total Assets 
124,485,493
119,822,987
111,420,021
97,851,602
94,524,102
96,459,738
96,795,868
87,171,187
84,879,202
85,376,940
122,548,683
117,125,562
122,854,863
126,700,765
124,402,194
124,730,823
123,520,488
124,266,019
130,747,592
168,695,547
163,716,655
162,158,437
163,968,376
162,304,333
163,866,001
181,340,206
184,150,630
191,383,403
191,131,167
197,551,394
207,307,554
220,132,431
203,637,791
203,848,003
202,999,782
198,477,805
190,456,641
183,410,928
186,345,377
213,451,233
209,132,518
227,224,379
241,314,254
239,746,993
239,746,993241,314,254227,224,379209,132,518213,451,233186,345,377183,410,928190,456,641198,477,805202,999,782203,848,003203,637,791220,132,431207,307,554197,551,394191,131,167191,383,403184,150,630181,340,206163,866,001162,304,333163,968,376162,158,437163,716,655168,695,547130,747,592124,266,019123,520,488124,730,823124,402,194126,700,765122,854,863117,125,562122,548,68385,376,94084,879,20287,171,18796,795,86896,459,73894,524,10297,851,602111,420,021119,822,987124,485,493
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
96,436,379
95,429,756
96,556,991
103,342,138
138,372,087
133,471,892
130,977,715
132,907,727
128,408,636
123,633,512
138,985,215
138,447,375
134,295,046
134,161,959
129,040,241
129,471,134
129,364,552
131,328,054
130,335,749
128,300,168
118,814,676
113,524,784
106,405,503
105,698,222
111,788,673
106,645,389
118,136,154
110,792,156
113,577,189
113,577,189110,792,156118,136,154106,645,389111,788,673105,698,222106,405,503113,524,784118,814,676128,300,168130,335,749131,328,054129,364,552129,471,134129,040,241134,161,959134,295,046138,447,375138,985,215123,633,512128,408,636132,907,727130,977,715133,471,892138,372,087103,342,13896,556,99195,429,75696,436,379000000000000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
9,499,038
11,295,739
11,293,171
14,207,003
41,922,274
14,541,439
10,662,378
9,903,753
22,682,394
19,028,848
10,935,077
21,375,563
6,120,056
9,323,259
9,442,422
6,983,408
4,200,417
10,543,394
7,927,429
12,834,923
12,794,274
20,537,862
16,615,998
17,746,457
16,840,782
22,225,917
16,368,696
33,802,878
33,722,514
33,722,51433,802,87816,368,69622,225,91716,840,78217,746,45716,615,99820,537,86212,794,27412,834,9237,927,42910,543,3944,200,4176,983,4089,442,4229,323,2596,120,05621,375,56310,935,07719,028,84822,682,3949,903,75310,662,37814,541,43941,922,27414,207,00311,293,17111,295,7399,499,038000000000000000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
37,420,000
27,722,160
37,204,160
46,653,960
52,166,330
73,916,729
74,372,263
81,062,352
66,673,300
65,902,577
77,666,800
85,515,500
89,313,090
89,146,802
81,837,450
81,463,390
86,505,315
83,888,652
79,819,521
74,735,925
67,775,273
55,082,547
48,576,978
48,921,715
37,093,287
37,341,976
37,504,661
27,606,514
22,774,597
22,774,59727,606,51437,504,66137,341,97637,093,28748,921,71548,576,97855,082,54767,775,27374,735,92579,819,52183,888,65286,505,31581,463,39081,837,45089,146,80289,313,09085,515,50077,666,80065,902,57766,673,30081,062,35274,372,26373,916,72952,166,33046,653,96037,204,16027,722,16037,420,000000000000000000
       Net Receivables 
26,201,711
26,595,707
26,286,795
23,169,819
25,373,435
27,265,397
28,635,662
28,952,905
28,725,662
29,147,695
26,136,580
23,439,966
24,096,293
22,047,830
21,033,490
22,485,829
19,408,770
20,263,142
20,789,585
18,954,671
19,381,098
20,049,532
17,535,086
17,522,294
17,686,726
26,917,337
13,819,565
22,630,237
14,943,787
17,929,427
18,875,958
15,728,664
13,076,540
17,350,511
16,032,819
15,554,722
15,114,874
17,201,162
14,959,685
30,709,424
13,461,493
29,525,414
15,393,264
15,630,329
15,630,32915,393,26429,525,41413,461,49330,709,42414,959,68517,201,16215,114,87415,554,72216,032,81917,350,51113,076,54015,728,66418,875,95817,929,42714,943,78722,630,23713,819,56526,917,33717,686,72617,522,29417,535,08620,049,53219,381,09818,954,67120,789,58520,263,14219,408,77022,485,82921,033,49022,047,83024,096,29323,439,96626,136,58029,147,69528,725,66228,952,90528,635,66227,265,39725,373,43523,169,81926,286,79526,595,70726,201,711
       Other Current Assets 
2,367,367
2,253,383
2,134,067
2,051,953
2,152,235
1,745,803
1,595,010
1,512,509
1,529,545
1,264,783
1,168,346
1,145,959
1,298,576
2,372,363
2,449,330
1,381,288
1,561,015
1,484,727
1,317,228
7,368,539
8,595,113
2,127,055
2,042,617
4,690,971
553,250
409,871
1,744,163
2,482,288
3,225,230
2,579,669
2,325,471
2,895,949
2,487,222
2,379,936
2,171,284
2,140,769
3,461,827
3,031,229
2,212,373
1,834,970
154,089
152,386
157,266
179,635
179,635157,266152,386154,0891,834,9702,212,3733,031,2293,461,8272,140,7692,171,2842,379,9362,487,2222,895,9492,325,4712,579,6693,225,2302,482,2881,744,163409,871553,2504,690,9712,042,6172,127,0558,595,1137,368,5391,317,2281,484,7271,561,0151,381,2882,449,3302,372,3631,298,5761,145,9591,168,3461,264,7831,529,5451,512,5091,595,0101,745,8032,152,2352,051,9532,134,0672,253,3832,367,367
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
40,232,489
42,354,991
45,703,256
57,088,357
56,969,208
68,511,153
77,836,420
90,767,879
72,309,737
73,512,254
74,699,613
79,663,130
76,931,857
77,005,425
80,647,155
101,662,559
102,487,128
109,088,225
130,522,099
126,169,803
126,169,803130,522,099109,088,225102,487,128101,662,55980,647,15577,005,42576,931,85779,663,13074,699,61373,512,25472,309,73790,767,87977,836,42068,511,15356,969,20857,088,35745,703,25642,354,99140,232,489000000000000000000000000
       Property Plant Equipment 
10,706,570
10,637,100
11,407,994
12,203,730
12,166,768
12,014,226
12,087,501
11,859,485
11,699,954
12,462,091
12,255,476
12,178,702
12,006,047
12,324,628
13,150,090
13,779,348
13,653,081
13,389,369
12,996,651
13,378,138
13,402,296
13,658,929
13,684,107
13,768,867
14,479,851
14,292,948
14,643,363
14,936,210
15,112,758
15,444,862
15,669,017
15,480,480
14,384,130
15,339,760
16,658,801
19,044,879
19,237,321
19,285,927
18,878,527
19,126,408
18,996,220
18,832,041
19,237,107
19,433,937
19,433,93719,237,10718,832,04118,996,22019,126,40818,878,52719,285,92719,237,32119,044,87916,658,80115,339,76014,384,13015,480,48015,669,01715,444,86215,112,75814,936,21014,643,36314,292,94814,479,85113,768,86713,684,10713,658,92913,402,29613,378,13812,996,65113,389,36913,653,08113,779,34813,150,09012,324,62812,006,04712,178,70212,255,47612,462,09111,699,95411,859,48512,087,50112,014,22612,166,76812,203,73011,407,99410,637,10010,706,570
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,781,738
1,509,578
1,539,578
1,569,578
1,760,892
1,790,892
2,861,792
2,834,949
6,140,566
11,838,954
11,983,441
11,881,341
17,929,210
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000017,929,21011,881,34111,983,44111,838,9546,140,5662,834,9492,861,7921,790,8921,760,8921,569,5781,539,5781,509,5781,781,738000000000000000
       Intangible Assets 
2,693,400
3,189,571
3,132,006
3,736,935
3,616,615
3,603,275
3,572,463
3,385,474
3,244,838
2,999,977
2,816,923
2,712,673
1,330,235
2,677,632
2,376,069
3,623,909
3,454,693
3,298,182
3,336,050
3,420,507
3,280,275
3,202,857
3,062,427
3,257,910
5,551,315
6,479,332
9,815,732
10,717,772
10,688,890
13,981,656
14,282,773
15,077,815
15,496,560
17,722,285
17,998,520
19,096,113
19,523,122
20,995,629
22,935,836
23,838,878
25,934,336
28,376,480
29,352,299
32,609,078
32,609,07829,352,29928,376,48025,934,33623,838,87822,935,83620,995,62919,523,12219,096,11317,998,52017,722,28515,496,56015,077,81514,282,77313,981,65610,688,89010,717,7729,815,7326,479,3325,551,3153,257,9103,062,4273,202,8573,280,2753,420,5073,336,0503,298,1823,454,6933,623,9092,376,0692,677,6321,330,2352,712,6732,816,9232,999,9773,244,8383,385,4743,572,4633,603,2753,616,6153,736,9353,132,0063,189,5712,693,400
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
-1
4,405,300
0
1
0
0
-1
0
0
0
-1
0
0
0
0
1
0
0
-1
-10010000-1000-100104,405,300-11000000000000000000000000
> Total Liabilities 
43,764,422
41,965,701
38,607,281
38,225,375
35,313,249
36,984,403
37,181,032
41,361,752
38,652,527
37,537,271
20,105,935
21,909,163
20,953,140
22,389,116
20,227,988
20,373,366
19,390,735
19,538,209
23,075,364
57,497,661
51,697,525
47,309,200
46,449,957
45,386,081
43,451,291
56,563,297
53,875,121
50,965,912
45,690,716
40,776,989
39,185,275
38,858,948
40,144,366
41,280,015
39,123,981
34,985,662
35,313,891
32,777,585
32,312,161
45,194,772
43,323,114
49,927,695
43,630,317
53,528,623
53,528,62343,630,31749,927,69543,323,11445,194,77232,312,16132,777,58535,313,89134,985,66239,123,98141,280,01540,144,36638,858,94839,185,27540,776,98945,690,71650,965,91253,875,12156,563,29743,451,29145,386,08146,449,95747,309,20051,697,52557,497,66123,075,36419,538,20919,390,73520,373,36620,227,98822,389,11620,953,14021,909,16320,105,93537,537,27138,652,52741,361,75237,181,03236,984,40335,313,24938,225,37538,607,28141,965,70143,764,422
   > Total Current Liabilities 
39,164,249
37,047,097
33,365,701
32,945,715
30,258,324
31,880,432
31,039,551
33,192,252
29,727,686
28,889,734
14,284,506
14,082,156
12,849,074
13,875,024
11,472,603
14,393,784
13,045,317
12,567,202
15,766,344
52,788,363
46,926,221
42,212,448
40,844,879
21,805,136
18,834,900
28,094,189
25,927,415
27,384,697
24,061,963
21,216,163
21,731,702
23,069,434
26,344,474
25,152,559
24,463,346
22,119,700
24,348,364
23,331,198
24,585,066
28,534,710
28,649,918
32,695,508
28,965,524
37,651,870
37,651,87028,965,52432,695,50828,649,91828,534,71024,585,06623,331,19824,348,36422,119,70024,463,34625,152,55926,344,47423,069,43421,731,70221,216,16324,061,96327,384,69725,927,41528,094,18918,834,90021,805,13640,844,87942,212,44846,926,22152,788,36315,766,34412,567,20213,045,31714,393,78411,472,60313,875,02412,849,07414,082,15614,284,50628,889,73429,727,68633,192,25231,039,55131,880,43230,258,32432,945,71533,365,70137,047,09739,164,249
       Accounts payable 
3,555,932
2,099,336
3,627,842
3,206,298
3,100,868
5,337,834
3,302,716
6,404,564
2,822,424
3,881,918
3,888,646
4,816,427
3,750,248
5,898,138
3,967,362
6,517,766
5,229,477
5,626,377
5,378,308
5,152,877
6,063,769
5,446,700
4,895,404
2,830,064
3,350,420
0
0
4,299,725
6,950,674
2,230,587
3,461,183
4,946,351
4,694,830
5,337,166
3,622,700
1,759,329
3,318,320
4,907,201
4,159,665
4,754,870
6,768,529
4,695,070
4,915,881
11,272,575
11,272,5754,915,8814,695,0706,768,5294,754,8704,159,6654,907,2013,318,3201,759,3293,622,7005,337,1664,694,8304,946,3513,461,1832,230,5876,950,6744,299,725003,350,4202,830,0644,895,4045,446,7006,063,7695,152,8775,378,3085,626,3775,229,4776,517,7663,967,3625,898,1383,750,2484,816,4273,888,6463,881,9182,822,4246,404,5643,302,7165,337,8343,100,8683,206,2983,627,8422,099,3363,555,932
       Other Current Liabilities 
10,391,891
9,883,167
12,586,659
12,459,222
9,877,261
8,695,755
9,019,713
9,593,290
9,705,188
10,143,816
10,395,860
9,265,729
9,098,826
7,976,886
7,505,241
7,876,018
7,815,840
6,940,825
10,388,036
47,635,486
40,862,452
35,536,124
34,680,439
17,023,702
1
0
0
20,850,048
15,227,551
16,709,011
15,500,489
15,742,867
18,893,838
16,388,925
17,580,719
17,790,059
19,386,060
16,151,165
18,129,575
21,097,895
1,850,316
0
0
2,097,298
2,097,298001,850,31621,097,89518,129,57516,151,16519,386,06017,790,05917,580,71916,388,92518,893,83815,742,86715,500,48916,709,01115,227,55120,850,04800117,023,70234,680,43935,536,12440,862,45247,635,48610,388,0366,940,8257,815,8407,876,0187,505,2417,976,8869,098,8269,265,72910,395,86010,143,8169,705,1889,593,2909,019,7138,695,7559,877,26112,459,22212,586,6599,883,16710,391,891
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
24,616,391
28,469,109
27,947,706
23,581,216
21,628,753
19,560,826
17,453,573
15,789,514
13,799,892
16,127,456
14,660,635
12,865,962
10,965,528
9,446,387
7,727,095
16,660,062
14,673,196
17,232,188
14,664,793
15,876,753
15,876,75314,664,79317,232,18814,673,19616,660,0627,727,0959,446,38710,965,52812,865,96214,660,63516,127,45613,799,89215,789,51417,453,57319,560,82621,628,75323,581,21627,947,70628,469,10924,616,391000000000000000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
613,693
591,673
505,020
568,183
608,086
694,537
559,264
551,514
482,574
1,681,069
1,501,186
1,335,113
1,236,255
1,245,664
1,088,268
1,310,400
1,287,082
1,263,055
1,113,885
1,290,530
1,290,5301,113,8851,263,0551,287,0821,310,4001,088,2681,245,6641,236,2551,335,1131,501,1861,681,069482,574551,514559,264694,537608,086568,183505,020591,673613,693000000000000000000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-1
0
-1
-1
0
0
1
0
0
0
000100-1-10-10000000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
8,030,171
8,439,536
8,498,701
8,514,945
6,740,229
6,740,228
6,740,229
6,740,229
2,266,858
2,266,858
0
0
7,666,348
7,731,334
11,120,879
0
12,480,670
13,004,038
0
0
16,876,865
17,374,084
0
0
21,775,541
0
0
0
0
000021,775,5410017,374,08416,876,8650013,004,03812,480,670011,120,8797,731,3347,666,348002,266,8582,266,8586,740,2296,740,2296,740,2286,740,2298,514,9458,498,7018,439,5368,030,171000000000000000
> Total Stockholder Equity
80,721,071
77,857,286
72,812,740
59,626,226
59,210,853
59,475,335
59,614,835
45,809,435
46,226,675
47,839,669
102,442,748
95,216,399
101,901,723
104,311,650
104,174,207
104,357,458
104,129,752
104,727,809
107,672,228
111,197,886
112,019,130
114,849,237
117,518,419
116,918,253
120,414,710
124,776,909
130,275,509
140,417,491
145,440,451
156,774,405
168,122,279
181,273,483
163,493,425
162,567,988
163,875,801
163,492,144
155,142,750
150,633,343
154,033,216
168,256,461
165,809,404
177,296,684
197,683,938
186,218,370
186,218,370197,683,938177,296,684165,809,404168,256,461154,033,216150,633,343155,142,750163,492,144163,875,801162,567,988163,493,425181,273,483168,122,279156,774,405145,440,451140,417,491130,275,509124,776,909120,414,710116,918,253117,518,419114,849,237112,019,130111,197,886107,672,228104,727,809104,129,752104,357,458104,174,207104,311,650101,901,72395,216,399102,442,74847,839,66946,226,67545,809,43559,614,83559,475,33559,210,85359,626,22672,812,74077,857,28680,721,071
   Common Stock
20,857,369
20,901,869
20,901,869
20,901,869
20,901,869
20,901,869
20,901,869
20,901,869
20,901,869
21,017,378
25,767,378
25,767,378
26,120,319
26,120,319
26,120,319
26,120,319
26,120,319
26,120,319
26,120,319
26,120,319
26,120,319
26,120,319
26,120,319
26,120,319
26,120,319
26,120,319
26,120,319
26,120,319
26,120,319
26,120,319
26,120,319
26,120,319
26,120,319
26,120,319
26,120,319
26,120,319
26,120,319
26,120,319
26,120,319
26,120,319
0
0
0
0
000026,120,31926,120,31926,120,31926,120,31926,120,31926,120,31926,120,31926,120,31926,120,31926,120,31926,120,31926,120,31926,120,31926,120,31926,120,31926,120,31926,120,31926,120,31926,120,31926,120,31926,120,31926,120,31926,120,31926,120,31926,120,31926,120,31926,120,31926,120,31925,767,37825,767,37821,017,37820,901,86920,901,86920,901,86920,901,86920,901,86920,901,86920,901,86920,901,86920,857,369
   Retained Earnings 
1,242,911
1,162,290
1,323,550
1,432,170
1,523,689
1,681,597
1,560,845
1,587,156
1,051,378
1,139,467
953,917
1,022,844
994,027
638,125
566,523
325,731
268,375
227,656
122,125
5,077
548,887
-20,600,356
-18,050,203
-21,338,566
-20,258,978
-13,844,820
-8,387,801
-3,108,972
770,867
6,667,598
10,381,538
17,587,267
22,115,765
25,376,923
27,436,691
26,379,452
26,296,677
26,222,376
26,956,744
29,408,688
28,158,073
35,449,143
35,783,355
31,364,999
31,364,99935,783,35535,449,14328,158,07329,408,68826,956,74426,222,37626,296,67726,379,45227,436,69125,376,92322,115,76517,587,26710,381,5386,667,598770,867-3,108,972-8,387,801-13,844,820-20,258,978-21,338,566-18,050,203-20,600,356548,8875,077122,125227,656268,375325,731566,523638,125994,0271,022,844953,9171,139,4671,051,3781,587,1561,560,8451,681,5971,523,6891,432,1701,323,5501,162,2901,242,911
   Capital Surplus 00000000000000000000000000000000000000000000
   Treasury Stock000000000000000000000-3,346,577-3,346,577-3,346,577-3,346,577-3,346,577-3,563,649-3,658,028-3,799,596-4,161,383-4,287,221-4,743,387-4,822,036-4,823,609-5,010,794-5,010,794-5,010,794-5,010,794-5,010,794-4,946,321-3,866,815-3,065,963-3,065,963-1,085,245
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
362,521
297,162
258,597
154,052
528,505
193,349
322,330
441,359
3,129,556
3,327,425
3,494,466
3,536,047
8,399,200
9,542,320
14,979,544
22,613,477
28,415,709
5,599,298
1,459,277
707,322
1,469,237
-608,879
-1,280,968
1,384,536
13,155,838
0
0
0
0
000013,155,8381,384,536-1,280,968-608,8791,469,237707,3221,459,2775,599,29828,415,70922,613,47714,979,5449,542,3208,399,2003,536,0473,494,4663,327,4253,129,556441,359322,330193,349528,505154,052258,597297,162362,521000000000000000



Balance Sheet

Currency in KRW. All numbers in thousands.




Cash Flow

Currency in KRW. All numbers in thousands.




Income Statement

Currency in KRW. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue134,909,838
Cost of Revenue-59,737,569
Gross Profit75,172,26875,172,268
 
Operating Income (+$)
Gross Profit75,172,268
Operating Expense-132,698,478
Operating Income2,211,359-57,526,210
 
Operating Expense (+$)
Research Development23,944,952
Selling General Administrative25,688,359
Selling And Marketing Expenses0
Operating Expense132,698,47849,633,311
 
Net Interest Income (+$)
Interest Income1,227,368
Interest Expense-63,863
Other Finance Cost-0
Net Interest Income1,163,505
 
Pretax Income (+$)
Operating Income2,211,359
Net Interest Income1,163,505
Other Non-Operating Income Expenses0
Income Before Tax (EBT)3,202,5322,211,359
EBIT - interestExpense = -63,863
3,508,608
3,572,471
Interest Expense63,863
Earnings Before Interest and Taxes (EBIT)03,266,395
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax3,202,532
Tax Provision--306,075
Net Income From Continuing Ops3,508,6083,508,608
Net Income3,508,608
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net0-1,163,505
 

Technical Analysis of Hanall
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Hanall. The general trend of Hanall is BULLISH with 14.3% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Hanall's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (14.3%) Bearish trend (-14.3%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Hanall Biopharma.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 41,550 < 41,600 < 46,750.

The bearish price targets are: 31,450 > 28,550 > 28,550.

Tweet this
Hanall Biopharma Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Hanall Biopharma. The current mas is .

The long score for the Moving Averages is 8/14.
The longshort score for the Moving Averages is 2/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Hanall Biopharma Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Hanall Biopharma. The current macd is -629.26862887.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Hanall price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Hanall. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Hanall price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Hanall Biopharma Daily Moving Average Convergence/Divergence (MACD) ChartHanall Biopharma Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Hanall Biopharma. The current adx is 15.31.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Hanall shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
Hanall Biopharma Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Hanall Biopharma. The current sar is 31,673.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Hanall Biopharma Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Hanall Biopharma. The current rsi is 52.13. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending up: The RSI is trending up. +1
Hanall Biopharma Daily Relative Strength Index (RSI) ChartHanall Biopharma Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Hanall Biopharma. The current phase is Overbought in bull market.

The long score for the Stochastic Oscillator is 5/6.
The longshort score for the Stochastic Oscillator is 4/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Hanall price going up in the near term. +2
  • Trending down: The STOCH %K is trending down. -1
Hanall Biopharma Daily Stochastic Oscillator ChartHanall Biopharma Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Hanall Biopharma. The current cci is 31.88.

Hanall Biopharma Daily Commodity Channel Index (CCI) ChartHanall Biopharma Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Hanall Biopharma. The current cmo is 12.37.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Hanall Biopharma Daily Chande Momentum Oscillator (CMO) ChartHanall Biopharma Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Hanall Biopharma. The current willr is -15.38461538.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Hanall Biopharma Daily Williams %R ChartHanall Biopharma Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Hanall Biopharma.

Hanall Biopharma Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Hanall Biopharma. The current atr is 1,772.

Hanall Biopharma Daily Average True Range (ATR) ChartHanall Biopharma Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Hanall Biopharma. The current obv is 34,634,044.

Hanall Biopharma Daily On-Balance Volume (OBV) ChartHanall Biopharma Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Hanall Biopharma. The current mfi is 49.98.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Hanall Biopharma Daily Money Flow Index (MFI) ChartHanall Biopharma Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Hanall Biopharma.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-30WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-01STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-04CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-05DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-12-06DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-08STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-11STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-18STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-20CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-27WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-03RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-01-04MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-15SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-19CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-25MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-29STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-30MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-31ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-01BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-02RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-05MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-06SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-13MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-15STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-19STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-20CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-23STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-27SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-28CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-29CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-05CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-07DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-08WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-11MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-12STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-15CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-21STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-25CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-27STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-01STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-03BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-12ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-15STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-16MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-17MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-19STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-23MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside

6.3. Candlestick Patterns

Hanall Biopharma Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Hanall Biopharma based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5052.127
Ma 20Greater thanMa 5034,392.500
Ma 50Greater thanMa 10035,830.000
Ma 100Greater thanMa 20035,759.500
OpenGreater thanClose35,350.000
Total4/5 (80.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Hanall with someone you think should read this too:
  • Are you bullish or bearish on Hanall? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Hanall? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Hanall Biopharma

I send you an email if I find something interesting about Hanall Biopharma.


Comments

How you think about this?

Leave a comment

Stay informed about Hanall Biopharma.

Receive notifications about Hanall Biopharma in your mailbox!